Medicare Claims for Duplicate Laboratory Services Continue to Be Denied
The Centers for Medicare & Medicaid Services (CMS) says it will continue to deny claims for duplicate laboratory services unless the tests are deemed...
1 min read
On May 29, Medicare announced it would expand coverage for genomic sequence analysis panels in the treatment of hematolymphoid diseases.
The local coverage determination (LCD) “provides limited coverage for genomic sequence analysis panels under specific clinical circumstances.” Specifically, these multi-gene panel tests would be used for diagnosis, risk stratification, and treatment planning for patients with hematolymphoid diseases, including newly diagnosed or relapsed/refractory acute myelogenous leukemia, myelodysplastic syndromes with nondiagnostic assessments, and myeloproliferative neoplasms requiring risk stratification or disease monitoring.
The College of American Pathologists applauded the proposed updates in a 2024 letter, expressing support for the decision to broaden coverage. According to CAP, the policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.
The revision is effective for services performed on or after July 13, 2025.
Sources:
https://www.cap.org/advocacy/latest-news-and-practice-data/june-10-2025#story5
CAP Submits Comments on Proposed 2027 Medicare Physician Fee Schedule
The College of American Pathologists (CAP) submitted comments to the proposed 2027 Medicare Physician Fee Schedule (PFS), addressing proposals that...
CMS Announces Phased-In Reduction of Medicare Payment Rates for Lab Services
The Centers for Medicare & Medicaid Services (CMS) plans to reduce preliminary Medicare payment rates for laboratory services.